22 Sept 2026, 5:37 pmInsider Trading / SAST
Closure of Trading Window
Closure of Trading Window PDF
Transgene Biotek Ltd operates in Healthcare Service Provider within the Healthcare sector.
2,420 historical price candles were omitted because the exchange source has not been verified.
Structured signal from quality, growth, valuation and momentum.
Comparable companies from the narrowest available industry classification.
Reported profit and loss, balance sheet, cash flow and growth history.
Annual operating, return, leverage and working-capital ratios.
Current futures and options contracts with compact option-chain pages.
Mutual-fund schemes that disclosed a holding in the company.
Annual reports, exchange filings, offer documents, ratings and earnings-call material.
Upcoming dates and the company’s corporate-action history.
Latest exchange announcements, filings and downloadable documents.
Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.
| Holder (%) | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 23.64% | 23.64% | 23.64% | 23.64% | 23.64% | 23.64% | 23.64% | 23.64% | 23.64% | 23.64% | 23.64% | 23.64% | |
| FII | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| DII | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| 76.36% | 76.36% | 76.36% | 76.36% | 76.36% | 76.36% | 76.36% | 76.36% | 76.36% | 76.36% | 76.36% | 76.36% | |
| No. of shareholders | — | — | — | — | — | — | — | — | 13,461 | 13,545 | 13,767 | 13,817 |
Promoter holding up 0 percentage points since Sep 2023.
| Date | Client | Type | Venue | Side | Quantity | Price | Value |
|---|---|---|---|---|---|---|---|
| 1 Dec 2023 | GEETANJALI INVESTMENTS | Bulk | BSE | Sell | 8,96,281 | ₹8.16 | ₹0.73 Cr |
| 1 Dec 2023 | MAYUR VIJAY PATWA | Bulk | BSE | Buy | 4,01,000 | ₹8.19 | ₹0.33 Cr |
| 1 Dec 2023 | SAHASRAR CAPITAL PRIVATE LIMITED | Bulk | BSE | Buy | 3,71,570 | ₹7.83 | ₹0.29 Cr |
| 24 Nov 2023 | GEETANJALI INVESTMENTS | Bulk | BSE | Sell | 7,16,159 | ₹9.10 | ₹0.65 Cr |
| 24 Nov 2023 | SAHASRAR CAPITAL PRIVATE LIMITED | Bulk | BSE | Buy | 3,50,000 | ₹9.12 | ₹0.32 Cr |
| 23 Nov 2023 | GEETANJALI INVESTMENTS | Bulk | BSE | Sell | 4,47,728 | ₹8.70 | ₹0.39 Cr |
Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.
Current officeholders as filed with BSE. A person holding two offices is listed once per office.
No scheme among the 32 fund houses on record reported a position in Transgene Biotek Ltd. Portfolios are published monthly by each AMC; coverage is still partial.
Documents link to external sources (exchange filings, company investor pages).
| Company | Mkt Cap | EV | Revenue | EBITDA | OPM | PAT | NPM | ROCE | ROE | WC Days |
|---|---|---|---|---|---|---|---|---|---|---|
| Dr. Lal Path Labs Ltd.LALPATHLABLALPATHLAB | ₹33,605 Cr | ₹33,605 Cr | ₹2,891 Cr | ₹838 Cr | 28.3% | ₹542 Cr | 18.5% | 28.8% | 21.6% | -79 |
| Vijaya Diagnostic Centre LimitedVIJAYAVIJAYA | ₹14,694 Cr | ₹14,694 Cr | ₹857 Cr | ₹362 Cr | 41.4% | ₹187 Cr | 21.3% | 21.3% | 19.7% | -117 |
| Metropolis Healthcare LimitedMETROPOLISMETROPOLIS | ₹11,151 Cr | ₹11,169 Cr | ₹1,710 Cr | ₹422 Cr | 24.4% | ₹202 Cr | 11.6% | 17.3% | 13.4% | -57 |
| Thyrocare Technologies LimitedTHYROCARETHYROCARE | ₹8,495 Cr | ₹8,495 Cr | ₹876 Cr | ₹282 Cr | 31.6% | ₹176 Cr | 19.6% | 36.5% | 28.8% | 4 |
| Nephrocare Health Services LimitedNEPHROPLUSNEPHROPLUS | ₹6,509 Cr | ₹6,589 Cr | ₹999 Cr | ₹227 Cr | 22.7% | ₹77 Cr | 7.7% | 17.1% | 9.1% | -61 |
| Suraksha Diagnostic LimitedSURAKSHASURAKSHA | ₹1,824 Cr | ₹1,826 Cr | ₹325 Cr | ₹102 Cr | 30.7% | ₹36 Cr | 10.1% | 16.8% | 14.1% | -101 |
| Krsnaa Diagnostics LimitedKRSNAAKRSNAA | ₹1,798 Cr | ₹2,332 Cr | ₹815 Cr | ₹218 Cr | 27.4% | ₹97 Cr | 13.1% | 13.1% | 10.9% | 65 |
| 3b Blackbio Dx Limited3BBLACKBIO3BBLACKBIO | ₹1,416 Cr | ₹1,417 Cr | ₹96 Cr | ₹50 Cr | 52% | ₹163 Cr | 49.4% | 25.3% | 19.4% | 235 |
| One Global Service Provider LtdONEGLOBALONEGLOBAL | ₹1,025 Cr | ₹1,025 Cr | ₹6 Cr | ₹1 Cr | 22.2% | ₹1 Cr | 17.3% | 17.6% | 19.5% | — |
| Health X Platform LimitedHEALTHXHEALTHX | ₹868 Cr | ₹890 Cr | ₹1,468 Cr | ₹-67 Cr | -4% | ₹-20 Cr | -0.1% | — | 0.2% | — |
| Gaudium Ivf And Women Health LimitedGAUDIUMIVFGAUDIUMIVF | ₹797 Cr | ₹820 Cr | ₹104 Cr | ₹38 Cr | 36.1% | ₹24 Cr | 23.4% | 23.1% | 16.1% | 92 |
| Aspira Pathlab & Diagnostics LtdASPIRAASPIRA | ₹135 Cr | ₹136 Cr | ₹22 Cr | ₹4 Cr | 16% | ₹2 Cr | 9.2% | 17.5% | 18.1% | 16 |
Ratios derive from annual statements, which haven't been ingested yet.
Closure of Trading Window
Closure of Trading Window
Announcement under Regulation 30 (LODR)-Newspaper Publication
1)The Board Considered And Approved The Unaudited Financial Results (Standalone & Consolidated) Of The Company For The Quarter Ended 30Th June 2026. 2) The Board Considered And Approved The Limited Review Report (Standalone & Consolidated) Of The Company For The Quarter Ended 30Th June 2026.
Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Directors Held On August 07, 2026.
Board Meeting Intimation for Intimation Of The Board Meeting.
Compliance-57 (4) : Prior intimation to the beginning of the quarter
Statement Of Deviation & Variation
| 11 Aug 2026, 12:52 pm | Company Update Newspaper Publication | Announcement under Regulation 30 (LODR)-Newspaper Publication |
| 7 Aug 2026, 11:55 am | Result Financial Results | 1)The Board Considered And Approved The Unaudited Financial Results (Standalone & Consolidated) Of The Company For The Quarter Ended 30Th June 2026. 2) The Board Considered And Approved The Limited Review Report (Standalone & Consolidated) Of The Company For The Quarter Ended 30Th June 2026. |
| 7 Aug 2026, 11:42 am | Board Meeting Outcome of Board Meeting | Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Directors Held On August 07, 2026. |
| 23 Jul 2026, 4:44 pm | Board Meeting | Board Meeting Intimation for Intimation Of The Board Meeting. |
| 22 Jul 2026, 1:44 pm | Others 57 (4) : Prior intimation to the beginning of the quarter | Compliance-57 (4) : Prior intimation to the beginning of the quarter |
| 22 Jul 2026, 1:40 pm | Company Update Reg. 32 (1), (3) - Statement of Deviation & Variation | Statement Of Deviation & Variation |
Standalone figures · ₹ crore · years without a filed annual are summed from quarters
| ₹ Cr | Mar 2017 | Mar 2019 | Mar 2021 | Mar 2022 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| 0 | — | 0 | 0 | 10 | 0 | 0 | |
| COGS | — | -0 | 0 | -0 | — | — | 0 |
| Gross profit | — | — | 0 | — | — | — | — |
| 20 | — | 1 | 1 | 23 | 1 | 1 | |
| -20 | — | -1 | -0 | -12 | -1 | -1 | |
| OPM % | — | — | -305.9% | -511.1% | -123.3% | -430.8% | -257.1% |
| Depreciation | — | — | 10 | 10 | 2 | 0 | 0 |
| Interest | — | — | 0 | 0 | 3 | 0 | 1 |
| — | — | 0 | 0 | 5 | 1 | 0 | |
| Profit before tax | -20 | -7 | -10 | -10 | -14 | -1 | -2 |
| Tax | — | — | 0 | 0 | — | — | 0 |
| PAT | -20 | -7 | -10 | -10 | -14 | -1 | -2 |
| PAT margin % | — | — | — | — | -135.1% | -261.5% | -785.7% |
| EPS (₹) | -0.9 | -0.5 | -1.4 | — | -0.1 | 0 | -0.2 |
| EPS adjusted (₹) | — | — | -1.4 | -1.4 | -1.8 | -0.1 | -0.2 |
| Annual report | Annual report for Mar 2017 | Annual report for Mar 2019 | Annual report for Mar 2021 | Annual report for Mar 2022 | Annual report for Mar 2024 | Annual report for Mar 2025 | — |
| ₹ Cr | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 76 | 76 | 76 | 76 | 76 | 76 |
| Reserves | -71 | -76 | -82 | -83 | -83 | -85 |
| 11 | 12 | 13 | 14 | 15 | 17 | |
| 31 | 25 | 26 | 25 | 27 | 26 | |
| Total equity & liabilities | 47 | 37 | 32 | 32 | 34 | 34 |
| 21 | 11 | 6 | 6 | 8 | 8 | |
| CWIP | — | — | 0 | — | — | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| 26 | 26 | 26 | 26 | 26 | 26 | |
| Total assets | 47 | 37 | 32 | 32 | 34 | 34 |
| ₹ Cr | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| 0 | 0 | 0 | 0 | 1 | -0 | |
| -0 | -0 | -0 | 0 | -2 | 0 | |
| 0 | 0 | 0 | 0 | 1 | -0 | |
| Net cash flow | -0 | 0 | -0 | 0 | 0 | -0 |
| Free cash flow | — | — | — | — | — | -0 |
| CFO / Operating profit % | — | — | — | — | — | — |